Helicobacter pylori (H. pylori) is a well-known pathogen that infects approximately half of the world's population. It is a pathogenic agent with potential health hazards related to diverse diseases, especially digestive diseases, such as chronic gastritis, peptic ulcer, and gastric carcinoma. In clinical, antibiotics are commonly applied in eradication therapy of H. pylori. However, the increase in antibiotic resistance and side effects has induced the failure of eradication therapy. Recent studies have shown that probiotic supplementation has promising application prospects. It can restore the gastrointestinal microbiota balance and prevent dysbacteriosis caused by antibiotics. Furthermore, it has been reported to have direct or indirect inhibitory effects on H. pylori. Probiotics may have a beneficial effect on H. pylori eradication. However, the strain, dosages, duration times, and safety of probiotic supplementation need further study before clinical applications.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640438 | PMC |
http://dx.doi.org/10.1007/s00203-022-03314-w | DOI Listing |
J Nanobiotechnology
December 2024
Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing, 100850, China.
In the post-COVID-19 era, drug-resistant bacterial infections emerge as one of major death causes, where multidrug-resistant Acinetobacter baumannii (MRAB) and drug-resistant Pseudomonas aeruginosa (DRPA) represent primary pathogens. However, the classical antibiotic strategy currently faces the bottleneck of drug resistance. We develop an antimicrobial strategy that applies the selective delivery of CRISPR/Cas9 plasmids to pathogens with biomimetic cationic hybrid vesicles (BCVs), irrelevant to bacterial drug resistance.
View Article and Find Full Text PDFBiomaterials
December 2024
Institute of Precision Medicine, Peking University Shenzhen Hospital, 518036, Shenzhen, China. Electronic address:
Radiotherapy, employing high-energy rays to precisely target and eradicate tumor cells, plays a pivotal role in the treatment of various malignancies. Despite its therapeutic potential, the effectiveness of radiotherapy is hindered by the tumor's inherent low radiosensitivity and the immunosuppressive microenvironment. Here we present an innovative approach that integrates peroxynitrite (ONOO)-mediated radiosensitization with the tumor-associated neutrophils (TANs) polarization for the reversal of immunosuppressive tumor microenvironment (TME), greatly amplifying the potency of radiotherapy.
View Article and Find Full Text PDFBiomater Adv
December 2024
Instituto de Investigaciones en Tecnologías Energéticas y Materiales Avanzados (IITEMA), Universidad Nacional de Río Cuarto and Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Campus Universitario, 5800 Río Cuarto, Argentina. Electronic address:
In this work the development of photoactive dressings (PAD) with dual purpose, is presented. These PAD can be used for the topical treatment of persistent infections caused by fungi and bacteria and are also applicable in light antitumor therapy for carcinoma. The synthesized PAD were designed employing conjugated polymer nanoparticles (CPN) doped with platinum porphyrin which serve as polymerization photoinitiators and photosensitizers for the production of reactive oxygen species (ROS).
View Article and Find Full Text PDFCont Lens Anterior Eye
December 2024
Department of Ophthalmology, Molecular Pharmacology and Physiology, FL, United States; Pathology and Cell Biology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.
Purpose: To evaluate the efficacy and safety of topical Ivermectin- Metronidazol in the management of demodex infestation and their effect in Meibomian gland dysfunction (MGD) METHODS: Fifty-four patients (108 eyes) with demodex diagnosis and Meibomian gland dysfunction received Ivermectin 0.3 %+Metronidazole 0.5 % gel in the night for 5 weeks.
View Article and Find Full Text PDFLancet Microbe
December 2024
Jiangxi Provincial Key Laboratory of Digestive Diseases, Department of Gastroenterology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Electronic address:
Background: Vonoprazan and amoxicillin (VA) dual therapy as a mainstream Helicobacter pylori regimen has gained momentum worldwide, but the optimum dosages remain unclear. We aimed to compare the efficacy and safety of VA dual therapy with 2 g amoxicillin or 3 g amoxicillin, and to assess the short-term effects of therapy on the gut microbiota and antibiotic resistome.
Methods: We conducted an open-label, non-inferiority randomised controlled trial at 12 centres in China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!